Saranac Partners’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$409K Sell
1,612
-14,020
-90% -$3.27M 0.12% 85
2026
Q1
$686K Buy
15,632
+13,995
+855% +$3.26M 0.29% 53
2025
Q4
$339K Buy
1,637
+155
+10% +$30.7K 0.13% 61
2025
Q3
$275K Buy
1,482
+110
+8% +$18.8K 0.05% 178
2025
Q2
$210K Buy
+1,372
New +$211K 0.11% 66
2023
Q4
– Sell
-1,376
Closed -$214K – 88
2023
Q3
$214K Hold
1,376
– – 0.12% 73
2023
Q2
$228K Hold
1,376
– – 0.12% 77
2023
Q1
$213K Buy
+1,376
New +$222K 0.13% 78

Other funds holding JNJ

Saranac Partners's JNJ Position: Q2 2026 in Review

Saranac Partners reduced its Johnson & Johnson (JNJ) stake by 90% in Q2 2026, selling an estimated $3.27M and leaving 1,612 shares worth $409K. The position accounts for 0.12% of the portfolio, ranked #85.

Saranac Partners first reported a position in JNJ in Q1 2023 and has held it in 8 quarters since. The position peaked at $686K in Q1 2026. 4,698 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Saranac Partners held 1,612 shares of Johnson & Johnson worth $409K as of Q2 2026.
  • Saranac Partners sold 14,020 Johnson & Johnson shares in Q2 2026, an estimated $3.27M.
  • Johnson & Johnson made up 0.12% of Saranac Partners's portfolio in Q2 2026, its #85 holding.
  • Saranac Partners first reported a position in Johnson & Johnson in Q1 2023 and has held it in 8 quarters since.
  • Saranac Partners's Johnson & Johnson position peaked at $686K in Q1 2026.
  • 4,698 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Saranac Partners's 13F filing for Q2 2026, filed 13 Aug 2026.